よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (90 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
30. Paul M, et al. European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gramnegative bacilli (endorsed by European society of intensive care medicine). Clin
Microbiol Infect. 2022. 28(4):521-547.
5
6
7
31. Onorato L, et al. Efficacy of ceftazidime/avibactam in monotherapy or combination
therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. Int J
Antimicrob Agents. 2019. 54(6):735-740.
8
9
10
32. Hsu W, et al. Ceftazidime-avibactam combination therapy versus monotherapy for
treating carbapenem-resistant gram-negative infection: a systemic review and metaanalysis. Infect. 2024. 52(5):2029-2042.
11
12
13
14
33. Bassetti M, et al. Efficacy and safety of cefiderocol or best available therapy for the
treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria
(CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive,
phase 3 trial. Lancet Infect Dis. 2021. 21(2):226-240.
15
16
17
34. Timsit JF, et al. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamaseProducing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized
Studies. Clin Infect Dis. 2022. 75(6):1081-1084.
18
19
20
35. Falcone M, et al. Clinical Features and Outcomes of Infections Caused by Metallo-βLactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic
Area. Clin Infect Dis. 2024. 78(5):1111-1119.
21
22
23
36. Tumbarello M, et al. Infections caused by KPC-producing Klebsiella pneumoniae:
differences in therapy and mortality in a multicentre study. J Antimicrob Chemother.
2015. 70(7):2133-2143.
24
25
26
27
37. Gutierrez-Gutierrez B, et al. Effect of appropriate combination therapy on mortality of
patients with bloodstream infections due to carbapenemase-producing
Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis.
2017. 17(7):726-734.
28
29
38. Kaye KS, et al. Colistin Monotherapy versus Combination Therapy for CarbapenemResistant Organisms. NEJM Evid. 2023. 2(1):10.1056/evidoa2200131.
30
31
32
39. Paul M, et al. Colistin alone versus colistin plus meropenem for treatment of severe
infections caused by carbapenem-resistant Gram-negative bacteria: an open-label,
randomised controlled trial. Lancet Infect Dis. 2018. 18(4):391-400.
33
34
40. Perez F, et al. Polymyxins: To Combine or Not to Combine? Antibiotics (Basel). 2019.
8(2):38.
35
36
37
41. Chen J, et al. Ceftazidime-avibactam versus polymyxins in treating patients with
carbapenem-resistant Enterobacteriaceae infections: a systematic review and metaanalysis. Infection. 2024. 52(1):19-28.
38
39
40
42. Chen Y, et al. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of
Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review
and Meta-Analysis. Microbiol Spectr. 2022. 27;10(2):e0260321.
41
42
43. Lima O, et al. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48
carbapenemase-producing Klebsiella pneumoniae. 2022. 41(9):1173-1182.
43
44
45
44. Gupta N, et al. Ceftazidime-avibactam and aztreonam combination for Carbapenemresistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase
production: a systematic review and meta-analysis. 2024. 22(4):203-209.
90
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
30. Paul M, et al. European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gramnegative bacilli (endorsed by European society of intensive care medicine). Clin
Microbiol Infect. 2022. 28(4):521-547.
5
6
7
31. Onorato L, et al. Efficacy of ceftazidime/avibactam in monotherapy or combination
therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. Int J
Antimicrob Agents. 2019. 54(6):735-740.
8
9
10
32. Hsu W, et al. Ceftazidime-avibactam combination therapy versus monotherapy for
treating carbapenem-resistant gram-negative infection: a systemic review and metaanalysis. Infect. 2024. 52(5):2029-2042.
11
12
13
14
33. Bassetti M, et al. Efficacy and safety of cefiderocol or best available therapy for the
treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria
(CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive,
phase 3 trial. Lancet Infect Dis. 2021. 21(2):226-240.
15
16
17
34. Timsit JF, et al. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamaseProducing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized
Studies. Clin Infect Dis. 2022. 75(6):1081-1084.
18
19
20
35. Falcone M, et al. Clinical Features and Outcomes of Infections Caused by Metallo-βLactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic
Area. Clin Infect Dis. 2024. 78(5):1111-1119.
21
22
23
36. Tumbarello M, et al. Infections caused by KPC-producing Klebsiella pneumoniae:
differences in therapy and mortality in a multicentre study. J Antimicrob Chemother.
2015. 70(7):2133-2143.
24
25
26
27
37. Gutierrez-Gutierrez B, et al. Effect of appropriate combination therapy on mortality of
patients with bloodstream infections due to carbapenemase-producing
Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis.
2017. 17(7):726-734.
28
29
38. Kaye KS, et al. Colistin Monotherapy versus Combination Therapy for CarbapenemResistant Organisms. NEJM Evid. 2023. 2(1):10.1056/evidoa2200131.
30
31
32
39. Paul M, et al. Colistin alone versus colistin plus meropenem for treatment of severe
infections caused by carbapenem-resistant Gram-negative bacteria: an open-label,
randomised controlled trial. Lancet Infect Dis. 2018. 18(4):391-400.
33
34
40. Perez F, et al. Polymyxins: To Combine or Not to Combine? Antibiotics (Basel). 2019.
8(2):38.
35
36
37
41. Chen J, et al. Ceftazidime-avibactam versus polymyxins in treating patients with
carbapenem-resistant Enterobacteriaceae infections: a systematic review and metaanalysis. Infection. 2024. 52(1):19-28.
38
39
40
42. Chen Y, et al. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of
Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review
and Meta-Analysis. Microbiol Spectr. 2022. 27;10(2):e0260321.
41
42
43. Lima O, et al. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48
carbapenemase-producing Klebsiella pneumoniae. 2022. 41(9):1173-1182.
43
44
45
44. Gupta N, et al. Ceftazidime-avibactam and aztreonam combination for Carbapenemresistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase
production: a systematic review and meta-analysis. 2024. 22(4):203-209.
90